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Abstract
The scientific literature has shown that diet is able to modify the gut microbiota and
contribute to obesity and diabetes development. This process—characterized by inflamma-
tion and gut barrier disruption—can affect the immune system and alter the adipogenesis
and insulin resistance. This chapter describes the advances in nutrigenomics and Human
Intestinal Microbiota (HIM) modification, and its relation with diabetes mellitus type two
(DM2). In context where health and feeding are the main concerns of the human being, food
innovation takes a special interest to people that look for a healthy diet or demand a
functional aliments, such as nutraceutical. Some products derived from diet and interaction
with HIM module the expression of many genes on the host, the so-called epigenome, with
favorable effects. Novel functional fiber like low-glycemic oligosaccharides and sweeteners
shows a potential prebiotic activity giving a new focus of nutritional guidelines for control
and prevention of DM2. The use of prebiotics derived from functional fiber sources, such as
fructo-oligosaccharides and beta-glucans as well as lignin and keffir, can contribute to the
development of a healthy HIM by promoting the growth of specific bacteria, some of them
associated with the prevention of obesity and diabetes.
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1. Introduction
Diabetes mellitus type two (DM2) is a complex pathology, it depends of the interaction of
genetic, epigenetic, environmental, and lifestyle factors [1]. This disease has generated an
epidemiological worldwide impact, with a current report of 425 million adults having the
disease according to the International Diabetes Federation (IDF). Currently, the last report of
the year 2017, the epidemiological data showed an increment of 10 million cases diagnosed
respect to 2015 [2]. According to the IDF, projection for 2045 is 650 million subjects with DM2.
North America and the Caribbean have the highest prevalence of this disease (11%), where an
increase of 62% is expected for the same period [3].
In the multidisciplinary treatment of this pathology, dietotherapy has been specifically consid-
ered as a critical control point in the international guidelines for DM2 [4, 5]. Recently, impor-
tant advances in nutrition management have been developed associated to nutritional
genomics, whose objective focuses on the interaction between the bioactive components of
food and the human genome, this approach includes studies of nutrigenetics, nutrigenomics,
and epigenetic modifications caused by nutrients [6].
Some investigations have used nutrigenomics to illustrate the modulation mechanism of
specific fatty acids on gene expression, producing an impact on human metabolism [7, 8]. A
common approach is the examination of individual levels of mRNA in relation to nutrient
intake [9]. Tests with carbohydrates and dietary components such as fiber show a relationship
between specific polymorphisms and the effect on insulin resistance [10]. In this sense, in a
recent review, the effectiveness of the supply of fermentable carbohydrates on human metab-
olism is explained [11].
Furthermore, new advances in study of the composition of the human microbiota have shown
an evident relationship between Human Intestinal Microbiota (HIM) and DM2 [12]. In this
context, a significantly greater association of Firmicutes/Bacteroidetes in DM2 has been
observed when is compared with normal weight and obese subjects [13].
New focus of nutritional treatment and its potential epigenetic effect constitute a panacea in
the modification of the diabetic patient’s microbiota [14]. The HIM is affected by the ingestion
of bioactive compounds, showing prebiotic or probiotic effects, whose action can help to
generate the growth of beneficial bacteria, such as Bifidobacterium and Bacteroidetes. The
development of personalized nutritional methods considering the genomic information, use
of prebiotics from novel sources of functional fibers (Fructo-oligosaccharides FOS, beta-
glucans) [15], consumption of carbohydrates with low-glycemic index (GI), as well as the use
of monosaccharide sweeteners with potential prebiotic activity, such as (tagatose) [16], would
allow to generate a new therapeutic orientation for the control and prevention of this pathol-
ogy. These dietary practices are important as part of the near future and will be analyzed in
this chapter. Finally, a description in nutrigenomics advances and the effect of prebiotics
consumption on modification of HIM are shown and its relationship with DM2 will be
discussed.
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2. Nutritional treatment and new perspectives
2.1. Prebiotics derived from functional fiber sources
A prebiotic is defined as “a non-digestible food ingredient that beneficially affects the host by
selectively stimulating the growth and/or activity of one or a limited number of bacteria in the
colon” [17]. Modification encouraged by prebiotics on the composition of HIM leads to the
predominance of a few of the potentially health-promoting bacteria, especially, but not exclu-
sively, Lactobacilli and Bifidobacteria [18]. Some prebiotics pass by the small intestine to the
lower gut and become accessible for probiotic bacteria without being utilized by other intesti-
nal bacteria [19]. Lactulose, galacto-oligosaccharides, fructo-oligosaccharides, inulin, and its
hydrolysates, malto-oligosaccharides, and resistant starch are prebiotics normally used in the
human diet [20, 21].
The definition used at present was given by the Food and Agriculture Organization of the
United Nations World Health Organization, according to which probiotics are redefined as
“live microorganisms which when are administered in adequate amounts confer a health
benefit on the host.” In relation to foods, the definition can be adjusted to beneficial effect
exerted bymicroorganisms “when are consumed in adequate amounts as part of food” [17, 21].
2.1.1. Betaglucans
2.1.1.1. Cereal β-glucans
Functional properties of β-glucans have been particularly attributed to the fact that these create
viscous solutions in aqueous solution, as occurs in the digestive tract [22, 23]. This viscosity
causes β-glucans to delay gastric emptying and interfere with the contact between pancreatic
enzymes and their substrates in the intestinal lumen, slowing the digestion and absorption
processes of nutrients [24]. This property could explain the effect of β-glucans on the reduction
of plasma cholesterol concentrations and the glycemic index [25, 26].
2.1.1.2. Yeasts and fungi β-glucans
Another pivotal property of fungi/yeasts β-glucans is the modulation of the immune system
[27, 28]. This effect could be due to the ability of β-glucans to stimulate receptors of the innate
immune system present in the membrane of enterocytes, M cells and dendritic cells, improving
the phagocytic activity of macrophages and antimicrobial activity of mononuclear cells and
neutrophils [29–31]. This type of β-glucans would also prevent the promotion and progression
of certain types of cancer, acting synergistically with monoclonal antibodies and chemother-
apy [32, 33]. This stimulation of immunity would be achieved by increasing the secretion of
pro-inflammatory cytokines and chemokines [34]. The main receptor involved in the effect of
B-glucans immunity is Dectin-1, even though there is also a role for the receptor 3 of the
complement, TLR-2, TLR-6 and the “scavengers” receptors [35, 36]. Dectin-1, known in human
beings as β-glucans receptor (βGR), is a member of the pattern recognition receptors (PRR)
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which fulfill an essential role in the innate immune response against viruses, bacteria, yeasts,
and fungi, contributing to the recognition and elimination of pathogens [34]. This receptor is
highly expressed in immune cells such as dendritic cells, neutrophils, eosinophils, and mono-
cytes as well as in some populations of T and B cells and, to a lesser extent, in macrophages and
enterocytes [31, 34, 35]. Dectin-1 acts through signal transduction activating Syk and RAF-1
[14]. It can also act synergistically with TLR which mediates the production of pro-
inflammatory cytokines, such as IL-12 and TNF-α [33, 35].
2.1.2. Fructo-oligosaccharides
Inulin is a non-digestible carbohydrate present in many vegetables, fruits, and cereals [36].
Currently, at the industrial level it is extracted from the chicory root (Cichorium intybus) and is
widely used as an ingredient in functional foods. Inulin and its derivatives (oligofructose,
fructo-oligosaccharides) are generally called fructans, basically composed of linear chains of
fructose [37]. The maximum dose allowed to be added to food formulated with inulin is up to
20 g/day for a simple dose and up to 10 g/day for multiple doses. At higher doses it can cause
intolerances after consumption, such as osmotic effects (diarrhea), intestinal noises and flatu-
lence as a result of the fermentation process [38]. Oligofructose is obtained by the partial
enzymatic hydrolysis of inulin, composed of linear chains of glucosyl-fructosil. GP ranges
between 2 and 8, with an average value of approximately [37]. It is present in foods such as
cereals, onions, garlic, banana, and corn [38, 39]. There are promising evidences of its perfor-
mance in the regulation of lipid parameters, reduction of the risk of cancer, reinforcement of
the immune response and protection against intestinal disorders [40]. In a wide variety of food
products, inulin and its derivatives are used as: thickener, emulsifier, gelling agent, sugar and
fat substitute, moisturizer, depressor of the freezing point [37, 39].
2.1.3. Lignin’s: mucilage’s (flaxseed)
2.1.3.1. Lignans
Plant lignans are phenolic compounds with a skeleton of 2,3-dibenzylbutane [40]. Flaxseed is
the richest food source in the precursors of lignans, secoisolariciresinol diglucoside (SDG), and
materesinol, which are phytoestrogens that by action of gastric acid and bacterial glucosidase
(facultative aerobics of Clostridia class) of the digestive tract transform into enterolactone and
enterodiol, respectively, known as lignans of mammals [41]. These have more antioxidant
capacity than their predecessors. Other lignans, such as lariciresinol, hinoquinina, arctigenin,
divanillyl tetrahydrofuran nordihydroguaiaretic acid, isolariciresinol, and pinoresinol, are also
present in flaxseed but the most abundant is SDG [40]. The health benefits of flaxseed lignans
rely in their antioxidant capacity as retainers of hydroxyl radicals, and as estrogenic and anti-
estrogenic compounds due to their structural similarity to the 17-β-estradiol [37, 41]. The
antioxidant activity of flaxseed lignan (SDG) is related to the suppression of the oxidizing
conditions of oxygen reactive species [41]. Secoisolariciresinol diglucoside and its aglycone
secoisolariciresinol show a high antioxidant capacity and protective effects to the damage of
the DNA and liposomes, especially in the epithelial cells of the colon exposed to these
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compounds, during the metabolism of the colon bacteria that transform them into lignans of
mammals [42, 43].
2.1.3.2. Mucilage
Mucilage is water-soluble polysaccharide present in many seeds, capable of absorbing 60–100
times their weight in water forming gels. They are formed by ramified arabinoxylans chains
[44]. The mucilage is similar to the gums, composed of galactose, mannose, xylose, and other
sugars [45]. One of the best known mucilage is psyllium (psyllium) or also called plantain,
coming from the seeds of Plantago genus [42, 44]. The mucilage extracted from algae contains
sugars somewhat different from terrestrial vegetables, such as agarobiose in the agar and sulf-
sugar in the carrageenan, used in food technology [44]. Flaxseed mucilage is a complex
polydisperse hydrocolloid and the different rheological behaviors observed in cultivars are
caused by the differences in the ratio between neutral and acid polymers and by the molecular
weight and structural conformation of polysaccharides [45, 46].
2.1.3.3. Flaxseed
Even though flaxseed is much known, it is not widely used in the formulation of food [47]. This
seed has significant amounts of bioactive compounds, such as alpha-linolenic acid, lignans and
dietary fiber, with potential effects in the prevention of some chronic diseases such as reducing
the risk of cardiovascular diseases, mitigating the effects of diabetes, renal pathologies, obesity,
colon and rectum cancer, reducing serum cholesterol level, and promoting the intestinal
evacuation [46, 47]. These characteristics make flaxseed an attractive source of ingredients to
be used in the elaboration of different functional foods [48].
2.1.4. Kefirs
Different in vitro and in vivo studies have demonstrated the ability of kefir to promote health
through the presence of bioactive peptides. Multiple bioactivities of this beverage such as
antihypertensive, antimicrobial, immune-modulating, mineral-carrying, antithrombotic, opi-
oid, and antioxidant have been the most reported [49]. These characteristics of kefir, along to
the pre- and probiotic properties, hypocholesterolemic, the bioavailability of milk components
with biological activity and the presence of metabolites such as organic acids and bacteriocins,
situate it as functional food [50]. This is a food that beyond the nutritional contribution of its
components has been proven to benefit one or more physiological functions of the organism,
improving the health, well-being, and/or reducing the risk to suffer diseases [51–53]. Addition-
ally, there are bioactivities that have been poorly studied as the mineral fixing properties
and the antithrombotic activity. There are some studies about the substrate-microorganism-
metabolite-bioactivity inter-relationships based on metagenome studies [54, 55]. It would be
important to carry out more investigations to determine the different bioactivities more deeply
and the effective dose by trying to reach the intestinal level in sufficient quantity to implant
and colonize its surface [56].
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2.2. Low-glycemic index of carbohydrates and inflammatory state intestinal mucose
2.2.1. Historic context glycemic index and glycemic load
One of the major dietary changes of the modern world has been the high consumption of
processed foods rich in carbohydrates and low in fiber; highly related to the increasing rates of
obesity and diabetes [49]. In this sense, pharmacological approaches focused on large clinical
trials have been useful for improving glycemic control in patients with type 2 diabetes (DM2)
[51]. Similarly, a positive effect in the control of diabetes has been associated with the con-
sumption of diets low in GI [52], these indicator determines the effect of the available carbohy-
drates in food on the average concentration of glucose in blood, this value is defined as the
relation between the area under the curve of 50 g of available carbohydrates in a food, with the
area under the curve of same amount of carbohydrates of a reference food [53].
White bread and glucose, which has been assigned a GI of 100, are considered reference foods
rather than a high value for this indicator [54]. Different entities worldwide, such as the
American Diabetes Association (ADA) [55], the European Association for the Study of Diabe-
tes [56], the Canadian Diabetes Association [57], and the UK Diabetes Nutrition Sub-
Committee [58] have prioritized dietary treatment with a relevant approach to carbohydrate
quality for the glycemic control, with special emphasis on reducing the digestion rate, absorp-
tion and metabolism of carbohydrates from foods [59].
Therefore, this indicator expresses the potential glycemia of a meal, representing the quality of
foods with predominance of carbohydrates [60]. Foods with carbohydrates capable of
digesting, absorbing and metabolizing quickly are considered food with high GI (GI ≥ 70 in
the glucose scale). Those between GI = 55 and 70 are considered in an intermediate value, while
those digested, absorbed and metabolized slowly are classified as foods with low GI (GI ≤ 55 in
the glucose scale) [53, 60]. There are international tables with the published values of this
indicator for a large number of products on the market. The first table was published in 1981
and was later updated in 1994 and 1995 [61, 62]. There is a marked controversy over the use of
this indicator in the decade of the 80, due to an inadequate interpretation of the evidence for its
determination [60, 63]. Criticism has focused on the methodological validity of the process to
quantify it since a large number of factors had influenced the results [60, 64]. The position of
the latest consensus of glycemic index experts in 925 held in Europe has determined that most
of the current critics are not valid, and that these reflect a failure of the knowledge translation
[60]. In this context, it is important to consider that important entities such as the International
Diabetes Federation have recognized the relevance of post-prandial regulation of glucose in
order to achieve the objectives of HBA1C by developing specific guidelines, whose manage-
ment is related to the GI concept [64].
2.2.2. Glycemic load, glycemic index, and insulin response
The value of glycemia and the insulin response depends on the quantity and quality of
carbohydrate and the mix of food ingested, the so-called glycemic load (GL). The GL represents
a relationship between the quantity and quality of carbohydrate [54, 60], and is defined as the
total carbohydrate content available in an amount of food (GL = GI  available carbohydrates/
specific amount of food) [60], and is the result of multiplying the amount of carbohydrate
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ingested in food by the value of its GI. The GL should be interpreted as a measure in the
demand for insulin, this value is a good indicator of the levels of post-prandial glycemia,
associated to the amount of calories in a particular portion of food or diet [65]. Thus, foods
with high GL and high GI have a direct effect on the development of hyperinsulinemia [66],
insulin resistance and risks to develop DM, which also have been linked to high-IG foods [67].
2.2.3. Insulin response and inflammation mucus and glycocalyx layer
Several studies have determined a clear link between the glycemic index and the glycemic load
of food and the insulin response [52, 68, 69]. Studies suggest that carbohydrates can modify the
microbiota, depending on their ability to increase glycemic and insulin response values
according to glycemic and insulinemic index [70, 71]. In this sense, several studies in rodents
have reported oligofructose as a recognized prebiotic, capable of modulating IM and improv-
ing insulin sensitivity [72, 73]. Similarly, inulin-type fructans have been tested to determine
their ability to modulate lipid metabolism and carbohydrate in various animal models [73, 74].
It has been reported that oligofructose (OFS) decreases the intake of food, the development of
fat mass and hepatic steatosis in normal and obese rodents. In addition, OFS exerts an
antidiabetic effect in rats treated with streptozotocin and mice treated with high content of fat
[72]. Chang et al. demonstrated that the addition of OFS also caused changes in the IM,
specifically for Bifidobacterium and Clostridium leptum [75] content. These results suggest that
OFS may be an effective therapeutic complement in the treatment of diabetes type 1 (DM1) by
improving insulin sensitivity and beta cell function, leading to better glycemic control [76]. OFS
reduced body weight, energy intake and fat mass in both phenotypes (P < 0.05) [76]. In another
study carried out in two different groups of rodents, OFS did not modify ghrelin in plasma, but
plasma levels of GIP were reduced and PYY were elevated (P < 0.05) [76] by OFS, reducing
body weight and adiposity in prone obese phenotypes and in those insulin-resistant [76].
The changes induced by this saccharide in the profiles of IM of these animals, along with the
changes of intestinal hormone levels probably contribute to lower body weights sustained
[76, 77]. Milk prebiotic oligosaccharides have been reported to alter the IM and may influence
the metabolism of the host. In a study performed in rats comparing diets with 15% of glucose,
fructose, galactose, and methylcellulose content, daily intake of 15% galactose improved the
sensitivity to hepatic insulin compared with glucose and fructose, producing an increase in the
content of hepatic glycogen in the feeding state and a positive change in the IM populations;
unlike the intake of galacto-oligosaccharides [78], which improved the IM profile without any
effect on the insulin sensitivity. The GI of lactose, fructose and isomaltose is (=43), (=20), and
(=2), respectively [62]. Further studies on these indicators are required in monosaccharides and
their effect on the human microbiome.
3. New perspectives in biotechnology of foods, low-glycemic index and the
microbiota
In context where health and feeding are the main concerns of the human being, food innova-
tion takes a special interest to people that look for a healthy diet or demands a greater number
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of functional products, such as nutraceutical, that often generates more contribution than
nutrients, helping to improve the prevent of different diseases [79].
A functional food has been defined as a: (i) natural food, (ii) food which a component with
some technology or biotechnology has been added or removed, (iii) food where the nature of
one or more components has been varied, (iv) food which the bioavailability of one or more of
its components has been modified, and/or (v) any combination of the above possibilities [80].
The world commercialization for functional foods and beverages have grown from $ 33 billion
in 2000 to 67.7 billion pesos in 2013, that mean the 5% of the global food commercialization,
and the growth of investment in food industry as a whole. Latin America is currently a
potential producer and consumer of functional foods, because of its large natural resources, a
wide biodiversity of flora and fauna having a variety of plants and edible fruits with potential
and beneficial effects for health [78].
Bioactive molecules works mainly modifying cellular signaling and causing changes in
expression of certain genes, for instance producing a defensive response to harmful pro-
cesses like differentiation and cell proliferation, inflammation, it is the base of the under-
standing for most prevalent diseases. New technology applied for food and nutrition
sciences are closely related to the biomedical area, researchers require strong training in
molecular biology, genetics and nutritional biochemistry, among others disciplines [81]. The
current “omics” technologies, such as genomics, transcriptomics, proteomics, metageno-
mics, metatranscriptomics and metabolomics, have introduced important strides in the
fields of health, biotechnology, ecology, and food [81]. The increase of the importance of
(I + D) from academy, where food and pharmaceutical industry have worked together to
promote healthy feeding, functional foods and nutraceuticals developing, those products
when are consumed in a regular way, contribute to the prevention and/or treatments of
certain diseases [82]. Genetic engineering plays an important role in the improvement of
functional foods, which involves biological and technological research and also normative
and ethical communication [83]. New probiotic strains isolated from natural niches and
other produced by genetically engineered organisms (GMOs) have broadened the spectrum
of organisms with improved probiotic properties for incorporation into functional foods
[84]. More than 500 probiotic food products have been introduced into the world stores over
the last couple of decades [81]. The contribution of biotechnology to production of prebiotics
is remarkable. Prebiotic such as inulin and fructose polymer are produced by extraction of
natural products (mainly chicory for fructose polymer), other prebiotics are produced by
bioprocesses involving microorganisms or enzymes specifically conditioned for efficient
synthesis of non-digestible oligosaccharides. On the other hand, inulin is the most used
prebiotic, although it is probably not the most effective, actually, in the formulation of
functional foods, also providing textural and rheological properties to the food matrix [83].
Another example of innovation is the design and development of product with intestinal
microbiota and/or GI control effects, such as powdered additive, that incorporates also
beneficial bacteria to the food. This development, achieved by researchers from National
Institute Food Technology in Chile and Conicet Argentina, incorporated as an additive to
certain foods—cold or lukewarm liquids—enriches the digestive system, balances the intes-
tinal microbiota with a positive impact on the immune system [85].
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3.1. Non-caloric sweeteners and gut microbiota
Non-caloric sweeteners (NCSs) are food additives widely used as sugar substitutes; these
sweeteners enhance tastes and simultaneously reduce calories consumption. Some epidemio-
logical studies have shown that artificial sweeteners are beneficial for weight loss, principally
for subjects having glucose intolerance and type 2 diabetes [86]. Historically, the consumption
of NCSs was restricted to people who have diseases such as diabetes; however, their consump-
tion has increased in recent decades for general population. For their approval for human
consumption, there are rigorous procedures required to consider them safe, however, today a
controversy exist in its safety and it has been noted the possibility that the NCSs alter intestinal
microbiota (IM). IM is involved in the metabolism of the host and plays a crucial role in food
digestion and energy homeostasis. However, multiple environmental factors, such as diet,
antibiotics and heavy metals, can disrupt the ecological balance of microbiota in the intestine
[87]. A study in male Sprague-Dawley rats who were subjected to oral probe of 100, 300, 500,
or 1000 mg/kg of Splenda for 12 weeks showed at the end of the treatment period, the number
of total anaerobes, Bifidobacteria, Lactobacilli, Bacteroides, Clostridia and total aerobic bacteria
decreased significantly. These changes occurred in Splenda doses containing sucralose at 1.1–
11 mg/kg (FDA’s acceptable daily intake for sucralose is 5 mg/kg) [88]. Other study realized in
8 weeks old C57B1 mice, two experiments were performed. Experiment 1, 4-week-old male
mice were divided into three groups (n = 8 x group) and treated for 8 weeks as follows: mice in
control group received distilled water; mice in the low dose sucralose group (LS) a sucralose
solution of 1.5 mg/kg body weight per day were given; and mice in the high-dose sucralose
group (HS) received a sucralose solution of 15 mg/kg body weight per day, which is equal to
the maximum IDA. In Experiment 2, 4-week-old male mice were divided into two groups and
treated for 8 weeks as follows: Mice in control group received distilled water (n = 8); and
acesulfame-K mice were given an acesulfame-K solution of 15 mg/kg body weight per day,
which is equal to the ADI (n = 9), resulting that consumption of sucralose, but not of
acesulfame-K, reduced the relative amount of Clostridium cluster XIVa in feces. Meanwhile,
sucralose and acesulfame-K did not increase food intake [89]. Acesulfame k is genotoxic, and
can inhibit the fermentation of glucose by intestinal bacteria [90]. A study in CD-1 mice
(~8 weeks of age), were given a dose of 37.5 mg/kg body weight/day of acesulfame-K during
4 weeks, in males Bacteroides showed increased instead in females mice drastically decreased
the relative abundance of multiple genres, including Lactobacillus, Clostridium, Ace-K disrupts
the composition of the intestinal microbiome in a sex-dependent manner [90]. Another study
in adult male C57B1/6 WT mice, gave two groups of mice a high in fat diet (60%) and
commercial saccharin (equivalent to one human IDA) or glucose [91], resulting in an alteration
in the glucose tolerance, the authors concluded that glucose intolerance was mediated by
change in the microbiota (increase of Bacteroidetes and Clostridium). To corroborate the latter, a
fecal transplantation to germ-free mice w performed, after 6 days an altered glucose tolerance
was present in these mice. A similar study was carried out this time in seven humans (five men
and two women), who were given 5 mg/kg/weight of saccharin (IDA equivalent) for 7 days,
four of whom had altered glycemic responses. Other study, carried out in 31 humans that
evaluated the consumption of aspartame and acesulfame k, showed that the consumers
of these NCSs presented a different bacterial diversity to those who did not consume these
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NCS [92]. This group also performed a smaller trial of seven healthy volunteers (five males,
two females, and ages 28–36) who did not normally consume NCS and who received saccharin
for 1 week at a dose of 5 mg/kg, IDA for these sweeteners. Most of these (4/7), known as “NCSs
responders” developed lower glucose tolerance and altered IM compared to “non-responders
of NCS” [92]. Microbiome of “NCS responders” showed changes in composition by 16S rRNA
analysis. Due this control group was not included in the design, it is unclear whether some
healthy individuals exposed to seven consecutive tests of oral glucose tolerance (daily intake of
75 g of glucose) would have developed changes in glucose metabolism in the absence of
saccharin. Palmnas et al. [107], demonstrated that 8 weeks of exposure to aspartame (at an
equal dose to subjects consuming approximately 2–3 sodas/day) disrupted the intestinal
microbiota; aspartame + high fat diet vs. water + high fat diet increased total bacteria; Entero-
bacteraceae, Clostridium leptum, and Roseburia spp. reduced Bifidobacterium sp. On the contrary,
when the diet was low fat + aspartame or low-fat + water, Clostridium leptum increased,
resulting in elevated levels of fasting glucose and insufficiency tolerance to insulin in rats [51].
However, the mechanism by which aspartame disrupted the IM is unclear, as aspartame is
metabolized before it reaches the colon by intestinal esterases and peptidases in amino acids
and methanol (Figure 1) [49].
3.2. Tagatose and prebiotic potential activity
D-tagatose (D-tag) is an isomer of fructose approximately 90% sweeter than sucrose. Only 20%
of the oral intake of tagatose is completely metabolized, mainly in the liver [49]. The mayor
part of this molecule is not digested or absorbed and passes through colon where water is
absorbed and D-tag is fermented by colonic bacteria. This natural sweetener can be artificially
Figure 1. NCSs: sucralose, saccharin and acesulfame-K have been found to modify the balance of the HIM, either by
decreasing or increasing the number of Bacteroidetes.
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obtained from lactose. This sweetener with natural origin can be obtained artificially from
lactose. Through food technology, glucose is separated and galactose is extracted, whose
molecule is transformed into D-tagatose through an isomerization process [43].
D-tag would have an antihyperglycemic potential through its beneficial effects increasing post-
prandial serum glucose and hyperinsulinemia. Recent studies indicate that D-tag has a potent
anti-diabetic effect and could be eventually associated with significant benefits for the treatment
of obesity. The hypothesis regarding the mechanism of action proposed for this hypoglycemic
effect would consider the interference with carbohydrates absorption by inhibition of intestinal
disaccharidases and glucose transport, an also a mechanism of inhibition of hepatic glycogenol-
ysis [37]. Another important characteristics of the D-tag is it lowGI, considering white bread and
glucose as reference foods, the D-tag GI is 3 and 4, respectively [63]. The potential applications of
D-tag in the pharmaceutical industry and in food industry have reached a great boom [41].
However, the use of D-tag is limited by its high cost of production [36]. Another characteristic
of D-tag is its potential prebiotic activity, and in order to preserve this effect the processing and
storing of the food must ensure the maintenance of the chemical structure of the sweetener [35].
It has been determined that D-tag can be used for the formulation of diabetic beverages with
minimal chance of degradation and very low loss of prebiotic activity [31, 33, 36], maintaining
adequate thermal stability. Preliminary results suggest that D-tag would have an effect on the
reduction of total cholesterol, VLDL, and LDL compared to sucrose in diabetic patients [53]; the
contribution of D-tag to increase levels of HDL cholesterol has also been shown [54]. These
clinical studies and wonderful advances in food technology make this molecule an ideal sweet-
ener in functional products for patients with diabetes [62–64], with the ability to positively affect
the intestinal microbiota of these patients, making its consumption more interesting and useful
in a little explored area [85, 87]. On the other hand, the incorporation of novel functional sources
of fiber, as well as oligosaccharides of potential prebiotic activity, has generated great scientific
interest in the formulation of healthy foods aimed at diabetics. This new direction of science
could be the anticipation of a new line of research that is beginning to emerge. Finally, future
projection of personalized nutrigenomics foresees a great challenge toward the integration of
different sciences as transcriptomics, epigenetics, proteomics, and metabolomics, with the pur-
pose of positively modifying the microbiome, generating impact in the gene expression of the
human organism, and avoiding manifestation of chronic diseases such as DM2.
4. Conclusions
The use of prebiotics obtained from functional fiber sources such as fructo-oligosaccharides
and beta-glucans, as well as lignin and prebiotics such as keffir, can contribute to the develop-
ment of a healthy HIM by promoting the growth of bacterial species that have been associated
with obesity and diabetes prevention. On the other hand, it has been described that some low
GI monosaccharides can positively modify the composition of the HIM in animal models, by
regulating the mechanism of insulin sensitivity. More investigations are needed to evaluate the
effect of saccharides, such as fructose, lactose and isomaltose in the human microbiome.
Although, some NCS such as sucralose, saccharin, and acesulfame-K can modify the balance
of HIM, mainly through the alteration in the number of Bacteroidetes species. Nevertheless,
more studies in humans are required. In this sense, a new caloric sugar called D-tag has proposed
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as possible hypoglycemic and probiotic effects. Finally, the new information presented in this
chapter allows us to map out the near future where the integration of nutrigenomics and
nutritional treatment focused on the microbiota modification will be plausible. Futhermore,
the use of bioactive compounds that alter gene expression and/or affects immunity of pancre-
atic beta cells represent a projection toward the treatment and/or prevention of DM2.
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